Janneke L.
- Country
- The Netherlands
- Department
- Internal medicine
Research Overview
- Pharmacokinetic Evaluation of Afamelanotide in Adolescent and Adult Patients with Erythropoietic Protoporphyria (EPP)
- APOLLO: A Randomized, Double-Blind, Placebo-Controlled Study of Bitopertin to Evaluate the Efficacy, Safety, and Tolerability in Participants with Erythropoietic Protoporphyria (EPP) or X-Linked Protoporphyria (XLP)
- An Open-Label Study to Evaluate the Long-Term Safety and Efficacy of Bitopertin in Participants with Erythropoietic Protoporphyria or X-Linked Protoporphyria
Data & Insights
Has run more than one trial at 12 of 12 partner sites.
Specializations
Rare Disease Research
This investigator specializes in studying Erythropoietic Protoporphyria (EPP), a rare genetic disorder affecting light sensitivity and skin protection mechanisms.
- Genetic photodermatology
- Metabolic skin disorders
- Porphyria management
The research focuses on understanding disease mechanisms and evaluating therapeutic interventions for EPP patients.
Therapeutic Development
Primary research interest centers on afamelanotide as a therapeutic agent, with particular emphasis on its clinical applications in photoprotective treatment.
- Drug pharmacokinetics
- Therapeutic efficacy
- Patient response analysis
The investigator examines treatment outcomes across different age groups, including adolescents and adults.
Clinical Applications
Expertise in photoprotective therapeutics and their practical applications in managing light-sensitive conditions.
- Age-specific treatment responses
- Clinical effectiveness measurement
- Patient care optimization
Research encompasses comparative analysis of treatment effects across different patient populations.
Related Investigators
Researchers in similar fields or departments
Want to know more about this investigator?
We can share extended profile information and contact details.
Is something out of date?
Tell us what needs correcting and we'll update this profile.